English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Key Clinical Message  Sorafenib is the standard treatment of hepatocellular carcinoma ( HCC ). However, fibrolamellar  HCC  was not included in sorafenib trials. The case is a 26‐year‐old man with fibrolamellar  HCC , who had a cerebrovascular accident ( CVA ) while being treated with sorafenib. This illustrates a probable relationship between use of sorafenib and  CVA  in low cardiovascular risk patients.

Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma